S&P 500
(0.32%) 5 116.17 points
Dow Jones
(0.38%) 38 386 points
Nasdaq
(0.35%) 15 983 points
Oil
(-1.34%) $82.73
Gas
(6.55%) $2.05
Gold
(0.01%) $2 347.50
Silver
(-0.35%) $27.44
Platinum
(4.11%) $960.00
USD/EUR
(-0.22%) $0.933
USD/NOK
(-0.33%) $10.99
USD/GBP
(-0.54%) $0.796
USD/RUB
(1.55%) $93.30

Sanntidsoppdatering for Hikma Pharmaceuticals PLC [HKMPY]

Børs: OTC Sektor: Healthcare Industri: Drug Manufacturers—Specialty & Generic
Sist oppdatert15 apr 2024 @ 16:33

0.00% $ 46.50

Live Chart Being Loaded With Signals

Commentary (15 apr 2024 @ 16:33):

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms...

Stats
Dagens volum 33.00
Gjennomsnittsvolum 130.00
Markedsverdi 5.16B
Last Dividend $0.500 ( 2023-08-11 )
Next Dividend $0 ( N/A )
P/E 27.35
ATR14 $0 (0.00%)

Hikma Pharmaceuticals PLC Korrelasjon

10 Mest positive korrelasjoner
10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Hikma Pharmaceuticals PLC Økonomi

Annual 2023
Omsetning: $2.88B
Bruttogevinst: $1.39B (48.35 %)
EPS: $1.720
FY 2023
Omsetning: $2.88B
Bruttogevinst: $1.39B (48.35 %)
EPS: $1.720
FY 2022
Omsetning: $2.52B
Bruttogevinst: $1.24B (49.19 %)
EPS: $1.680
FY 2021
Omsetning: $2.55B
Bruttogevinst: $1.30B (50.96 %)
EPS: $3.57

Financial Reports:

No articles found.

Hikma Pharmaceuticals PLC Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0.380
(N/A)
$0
(N/A)
$0.740
(N/A)
$0
(N/A)
$0.500
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Hikma Pharmaceuticals PLC Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.96 - Stable (0.75%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend $0.150 2012-04-18
Last Dividend $0.500 2023-08-11
Next Dividend $0 N/A
Payout Date 2023-09-25
Next Payout Date N/A
# dividends 24 --
Total Paid Out $8.89 --
Avg. Dividend % Per Year 0.00% --
Score 3.65 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 4.96
Div. Directional Score 8.04 --
Next Divdend (Est)
(2024-06-21)
$0.505 Estimate 7.56 %
Dividend Stability
0.30 Poor
Dividend Score
3.65
Pay Frequency
Semi-Annually
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
MYBF Ex Dividend Knight 2023-10-04 Quarterly 0 0.00%
CODYY Ex Dividend Knight 2023-06-08 Sporadic 0 0.00%
SYIEY Ex Dividend Knight 2023-05-11 Annually 0 0.00%
HNHPF Ex Dividend Junior 2023-07-03 Annually 0 0.00%
ATLKY Ex Dividend Knight 2023-10-19 Semi-Annually 0 0.00%
OTGLY Ex Dividend Junior 2023-06-12 Annually 0 0.00%
DTCWY Ex Dividend Junior 2023-06-15 Annually 0 0.00%
TTDKF Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%
JMHLY Ex Dividend Knight 2023-08-16 Semi-Annually 0 0.00%
BNPQY Ex Dividend Junior 2023-05-18 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.06621.5008.6810.00[0 - 0.5]
returnOnAssetsTTM0.04051.2008.6510.00[0 - 0.3]
returnOnEquityTTM0.08641.500-0.151-0.227[0.1 - 1]
payoutRatioTTM0.723-1.0002.77-2.77[0 - 1]
currentRatioTTM1.5680.8007.165.73[1 - 3]
quickRatioTTM0.8900.8009.477.58[0.8 - 2.5]
cashRatioTTM0.1531.500-0.261-0.391[0.2 - 2]
debtRatioTTM0.254-1.5005.76-8.64[0 - 0.6]
interestCoverageTTM5.461.0009.099.09[3 - 30]
operatingCashFlowPerShareTTM4.792.008.4010.00[0 - 30]
freeCashFlowPerShareTTM2.962.008.5210.00[0 - 20]
debtEquityRatioTTM0.542-1.5007.83-10.00[0 - 2.5]
grossProfitMarginTTM0.4591.0005.695.69[0.2 - 0.8]
operatingProfitMarginTTM0.1651.0008.708.70[0.1 - 0.6]
cashFlowToDebtRatioTTM0.4441.0008.648.64[0.2 - 2]
assetTurnoverTTM0.6120.8009.257.40[0.5 - 2]
Total Score11.11

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM27.061.0007.370[1 - 100]
returnOnEquityTTM0.08642.50-0.0971-0.227[0.1 - 1.5]
freeCashFlowPerShareTTM2.962.009.0110.00[0 - 30]
dividendYielPercentageTTM3.051.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM4.792.008.4010.00[0 - 30]
payoutRatioTTM0.7231.5002.77-2.77[0 - 1]
pegRatioTTM1.9541.5000.3060[0.5 - 2]
operatingCashFlowSalesRatioTTM0.1851.0007.880[0.1 - 0.5]
Total Score4.96

Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Om Live Signaler

Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.

Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.